Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07577388

Bed Rest With a Short Cervix on Preterm Birth

Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.

The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.

The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).

The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.

Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.

Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.

The primary outcome is gestational age in days (continuous).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Pregnant women with gestational age 20+0 to 33+6

  • Cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies
  • Above 18 years of age
  • Reads and understands Danish or English

Treatment and study plan

Activity Restriction

Behavioral

Recommendation to restrict physical activity in pregnant women with a short cervix. This may include increased rest or bed rest according to local clinical practice.

Other names: Bed Rest, AR

No Activity Restriction

Behavioral

Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.

Other names: Activity, No Bed Rest, NAR

Primary outcomes

  1. Gestational age at birth

    Time frame: At birth (from inclusion until delivery)

    Gestational age at birth measured in completed days of pregnancy. This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).

Secondary outcomes

  1. Birth before 37 weeks of gestation

    Time frame: At birth

  2. Gestational age at birth, pooled

    Time frame: At birth (from inclusion until delivery)

    • 14+0-21+6 weeks
    • 22+0-27+6 weeks
    • 28+0-31+6 weeks
    • 32+0-36+6 weeks
    • Birth after 37+0 weeks of gestation
  3. Latency from inclusion to birth (days)

    Time frame: At birth (from inclusion until delivery)

  4. Onset of birth

    Time frame: At birth (from inclusion until delivery)

    • Spontaneous
    • Induction
    • Caesarean section
  5. Mode of birth

    Time frame: At birth (from inclusion until delivery)

    • Vaginal
    • Assisted vaginal
    • Planned caesarean section
    • Non planned caesarean section
  6. - Non-occipital presentation

    Time frame: At birth (from inclusion until delivery)

  7. Interventions during birth

    Time frame: At birth (from inclusion until delivery)

    • Oxytocin-infusion
    • Epidural anaesthesia
  8. Degree of birth tear

    Time frame: At birth (from inclusion until delivery)

    • No tear
    • 1. or 2. degree tear
    • 3. or 4. degree tear
  9. Maternal serious morbidity

    Time frame: From inclusion to 42 days after delivery

    Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications

  10. Umbilical cord arterial pH

    Time frame: At birth (from inclusion until delivery)

  11. EPDS depression score

    Time frame: From inclusion to 8 weeks after due date

  12. Bone turnover marker level

    Time frame: At inclusion and after 4 and 8 weeks.

    • Procollagen type 1 N-propeptide (PINP)
    • Carboxy-terminal telopeptide of type I collagen (CTX)
  13. Lumbar spine Z-score

    Time frame: 12 months after stopped breastfeeding

  14. Data from SENS activity tracker

    Time frame: At birth (from inclusion until delivery)

    Step count Time in supine position

  15. Neonatal mortality

    Time frame: At birth (from inclusion until delivery)

  16. Fetal loss

    Time frame: At birth (from inclusion until delivery)

  17. Birth weight

    Time frame: At birth (from inclusion until delivery)

  18. Neonatal admission, days

    Time frame: From inclusion until discharge or 44 postmenstrual weeks

  19. CNS morbidity

    Time frame: From inclusion until discharge or 44 postmenstrual weeks

    Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia

  20. Gastrointestinal morbidity

    Time frame: From inclusion until discharge or 44 postmenstrual weeks

    Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment

  21. Respiratory support

    Time frame: From inclusion until discharge or 44 postmenstrual weeks

    Mechanical ventilation or non-invasive ventilation (NIV)

  22. Respiratory distress syndrome (RDS)

    Time frame: From inclusion until discharge or 44 postmenstrual weeks

  23. Early onset infection

    Time frame: From inclusion to 5 days after birth

    Definition: >5 days of i.v. antibiotics where the treatment starts within the first week after delivery.

  24. Apgar score at 5 minutes

    Time frame: At birth (from inclusion until delivery)

Study contacts

Contact information is provided by the study sponsor or research team.

Kirsten Bünemann, Medical Doctor, PhD-student

CONTACT

[email protected]

+45 40329849

Sponsors and collaborators

Lead sponsor

Julie Glavind

Other

Collaborators

  • Aalborg University Hospital
  • Aarhus University Hospital
  • Odense University Hospital
  • Rigshospitalet, Denmark
  • University of Aberdeen
  • Zealand University Hospital

Registry information

Official study title

BEWISE - Bed Rest With a Short Cervix on Preterm Birth

Acronym: BEWISE

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
May 11, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.